After Rebecca's " .... someone needs to teach me finance ... "...

First 31 Last

Share
Profile

Follow
Steini

12,673 Posts.

3867

22/08/24

10:59

Post #: 75321569
Share

Originally posted by Steini: ↑

IMU would pay with scrip, that would be an easy job. The problem would be the additional funding as just moving assets to IMU won't get rid of trial costs.

IMU's unofficial threshold, less than $100m, is already crossed and a CR is on the cards in the next 6-12 months as well. Finding at least an extra $50m for CHM plus $ 100m for IMU could be easy when Hopper was able to sell the 4 rego-trial drug candidates at the appropriate value. But so far his track record, apart of the VLA t/o, is terrible in that regard.

If the science wasn't that compelling, I would have moved on a long time ago. I sold a lot and kept just a small amount compared to what I had in 2021.

We still have the problem that he hasn't been able or willing to demand fair value for the data presented. He blames the market and then adds another huge discount, no wonder the valuations are down the drain when the chair himself is the biggest devaluer.

I was optimistic due to the RAD deal but watching that getting destroyed by the evil forces he himself knowingly invited makes me doubting what comes next.

GLTA

Expand

After Rebecca's " .... someone needs to teach me finance ... " comments I emailed her outlining the past raisings and asked her to keep an eye on the next moves by the board. I got a polite answer saying that the board is aware of what CHM is and should be worth. Let's see how much the board really values CHM.

GLTA

CHM Price at posting: 1.8¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

HAS

Hastings progressing Yangibana to production with lower costs

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The iron ore comeback: Can it last?

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 50 more messages in this thread...

First 31 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
1.4¢	1.5¢	1.4¢	$14.47K	1.027M

Buyers (Bids)

No.	Vol.	Price($)
1	391724	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	579596	1

View Market Depth

No.	Vol.	Price($)
1	391724	0.014
13	3124769	0.013
8	1386816	0.012
3	672817	0.011
4	485142	0.010

Price($)	Vol.	No.
0.015	579596	1
0.016	735854	3
0.017	647827	3
0.018	1788235	5
0.019	987804	3

Last trade - 16.10pm 30/09/2024 (20 minute delay)

CHM (ASX) Chart

After Rebecca's " .... someone needs to teach me finance ... "...

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Hastings progressing Yangibana to production with lower costs

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The iron ore comeback: Can it last?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

After Rebecca's " .... someone needs to teach me finance ... "...

Top Stories

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Hastings progressing Yangibana to production with lower costs

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The iron ore comeback: Can it last?

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News